Learning from BISCAY: The future of biomarker-based trial design in bladder cancer.

Meza, Luis; Salgia, Nicholas J; Patel, Kalen C; Pal, Sumanta K

Meza, Luis; Salgia, Nicholas J; Patel, Kalen C; Pal, Sumanta K.

Afiliação

Meza L; Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Salgia NJ; Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA; Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA.
Patel KC; Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Pal SK; Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. Electronic address: spal@coh.org.

Cancer Cell ; 39(7): 910-912, 2021 07 12.

Article em En | MEDLINE | ID: mdl-34256907

Assuntos

Carcinoma de Células de Transição; Neoplasias da Bexiga Urinária; Biomarcadores; Previsões; Humanos; Imunoterapia; Neoplasias da Bexiga Urinária/terapia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Carcinoma de Células de Transição Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google